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DISCUSSION AND CONCLUSION 
 We tested 15 subjects who subsequently developed 
primary EBV infection and from their incubational samples 
we were able to see immune responses prior to onset of 
symptoms. From our results we can see that antibody 
responses to VCA antigen p23 appear earlier than those 
to a different VCA antigen, p18. Subject 7141 is a good 
example of this finding, as we see the development of 
these bands before the subject is actually sick. For 7141, 
p23 and p54 develop at the same time, which is strongly 
indicative of an acute infection. Because of these early 
immune responses, we were able to better determine an 
estimate for when the subject became infected with EBV. 
From the results and insight gained from this study we are 
planning to look at how rapidity and intensity of antibody 
responses correspond to severity of illness.  
METHODS 
Samples were collected from EBV naïve freshmen 
students at the University of Minnesota during the 
2012-2013 academic school year. Antibody and antigen 
testing confirmed primary EBV infections. Of 87 subjects 
enrolled, 14 subsequently developed mononucleosis and 
1 was completely asymptomatic. After EBV-positive 
subjects were identified, selective samples were tested 
using Mikrogen recomLine EBV IgG kits that detect for 6 
EBV antigens associated with different stages of 
infection. Band intensity was assessed qualitatively and 
then scored as followed: 0 = no reactivity/negative. 1 = 
low band intensity/nonspecific cross reaction/negative. 2 
= equivalent to the cutoff band/likely positive. 3 = high 
intensity/positive. 4 =  strong intensity/strong positive. 
Subject 7141 developed an acute EBV infection on 11/8/12 and from their immunoblot we can see the development of immune 
response to early EBV antigens from 10/23/12 up until the time they show symptoms. 
Epstein-Barr virus (EBV) is a common human 
herpesvirus that infects 90% of adults worldwide and is 
most commonly known for causing infectious 
mononucleosis (mono). From our work studying EBV in 
a university setting since 2002, we know that college 
freshmen who have never been infected are at a high 
risk for mono. Having access to this population, we 
conducted a study to measure antibody responses to 
EBV antigens, such as BZLF1, p54 and EBNA-1, before, 
during and after EBV infection. Our results illustrate 
trends in antibody responses to these key EBV antigens 
that are consistent with our understanding of their 
activities during the different periods of infection. From 
this observation, we were able to better estimate the 
number of days since the start of primary EBV infection. 
These findings form the basis for further research on the 
variability of antibody responses between individuals 
with different severities of illness.  
EBV antibody responses to antigen during different 
stages of infection 
Subject 7040 was one of our sickest subjects. From their immunoblot we see that they don’t illicit any antibody responses during the 
first 35 days of their incubational period. However, during latency they have developed the full spectrum of EBV antibodies.  
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These graphs (below) represent the antibody responses to 3 EBV 
antigens – BZLF1, p54 and EBNA-1 – from our 15 EBV positive 
subjects. The x-axis represents time blocks of the different stages 
of infection as we define below: 
•  Incubational: start of infect, no symptoms. Days 0-42 
•  Acute: symptoms develop and last 2-4 weeks. Days 43-57 
•  Convalescent: symptoms end. Days 58-93 
•  Latent: viral infection ongoing but inactive. Days 94 onward 
BZLF-1 is an immediate early antigen (IEA) that is first detectable 
during the incubational and acute phases of infection.  
p54 is an early antigen (EA) that is a marker for acute infection 
EBNA-1 is the last to develop and confirms past EBV infection  
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